Concepedia

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study

Angela Huttner, Sélidji Todagbé Agnandji, Christophe Combescure, José F. Fernandes, Emmanuel B. Bache, Lumeka Kabwende, Francis M. Ndungu, Jessica S. Brosnahan, Thomas P. Monath, Barbara Lemaître,

The Lancet Infectious Diseases · 2018 · 82 citations · 17 references

DOIFull text

Open access

Concepts

References

17

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)

Ana María Henao-Restrepo, Anton Camacho, Ira M. Longini et al. · The Lancet · 2016 · 1.1K citations · Full text

, , +17

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

Sélidji Todagbé Agnandji, Angela Huttner, Madeleine E. Zinser et al. · New England Journal of Medicine · 2015 · 413 citations · Full text

, , +17

Late Ebola virus relapse causing meningoencephalitis: a case report

Michael Jacobs, Alison Rodger, David Bell et al. · The Lancet · 2016 · 356 citations · Full text

, , +17

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

Angela Huttner, Julie-Anne Dayer, Sabine Yerly et al. · The Lancet Infectious Diseases · 2015 · 278 citations

, , +16

Antibodies are necessary for rVSV/ZEBOV-GP–mediated protection against lethal Ebola virus challenge in nonhuman primates

Andrea Marzi, Flora Engelmann, Friederike Feldmann et al. · Proceedings of the National Academy of Sciences · 2013 · 268 citations · Full text

, , +17